Diagnosing mesothelioma has always been a unique challenge for doctors because the disease is usually not apparent until it has progressed to its advanced stages; however, Italian researchers have recently discovered a protein signal that could help doctors determine an individual’s risk for mesothelioma and make earlier detection possible.
The study consisted of three subject groups; patients suffering from malignant mesothelioma, workers who had been exposed to asbestos, and healthy individuals. Blood samples from all the subjects participating in the study were collected and the levels of various chemicals including signaling proteins called cytokines were tested. The researchers reported three significant findings in the online medical journal PLoS One.
More studies will need to be done, but there is a potential for RANTES to help doctors determine the patient’s risk for developing asbestos cancer based on the amount of RANKES in a patient’s blood. This protein could also hold the key to early detection of mesothelioma resulting in earlier treatment options and better prognosis for patients diagnosed with mesothelioma.
If you have been diagnosed with mesothelioma as a result of asbestos exposure, the Philadelphia asbestos lawyers at Brookman, Rosenberg, Brown & Sandler can help you obtain the compensation you deserve from those responsible for your exposure. Our experienced mesothelioma lawyers have been successfully representing clients with asbestos-related diseases for over 30 years. Our offices are located in Philadelphia, Pennsylvania, and we represent clients in Pennsylvania and New Jersey. Contact us online or call us at 215-569-4000 to review the details of your case.